AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,701,804 | +0.4% | 139,951 | +3.7% | 0.01% | +10.0% |
| Q2 2023 | $1,695,286 | +14.8% | 134,975 | +1.4% | 0.01% | 0.0% |
| Q1 2023 | $1,476,112 | -7.3% | 133,103 | +2.0% | 0.01% | -9.1% |
| Q4 2022 | $1,592,843 | +16.5% | 130,454 | -0.4% | 0.01% | +10.0% |
| Q3 2022 | $1,367,000 | -1.4% | 130,929 | +1.4% | 0.01% | +11.1% |
| Q2 2022 | $1,386,000 | +12.1% | 129,079 | -1.1% | 0.01% | +28.6% |
| Q1 2022 | $1,236,000 | -23.4% | 130,563 | -6.6% | 0.01% | -12.5% |
| Q4 2021 | $1,614,000 | +17.4% | 139,754 | -2.9% | 0.01% | +14.3% |
| Q3 2021 | $1,375,000 | -3.2% | 143,934 | -2.3% | 0.01% | +40.0% |
| Q2 2021 | $1,421,000 | -8.9% | 147,355 | -6.6% | 0.01% | 0.0% |
| Q1 2021 | $1,559,000 | -57.4% | 157,843 | -0.4% | 0.01% | -64.3% |
| Q4 2020 | $3,660,000 | +70.5% | 158,505 | +4.2% | 0.01% | +40.0% |
| Q3 2020 | $2,147,000 | -8.4% | 152,044 | -2.2% | 0.01% | -9.1% |
| Q2 2020 | $2,345,000 | +67.5% | 155,502 | +2.7% | 0.01% | +37.5% |
| Q1 2020 | $1,400,000 | -10.3% | 151,470 | -5.5% | 0.01% | +33.3% |
| Q4 2019 | $1,561,000 | +20.4% | 160,222 | -0.8% | 0.01% | +20.0% |
| Q3 2019 | $1,296,000 | -29.5% | 161,571 | +9.7% | 0.01% | -28.6% |
| Q2 2019 | $1,838,000 | +11.9% | 147,248 | +22.0% | 0.01% | +16.7% |
| Q1 2019 | $1,642,000 | +37.5% | 120,712 | -3.1% | 0.01% | +20.0% |
| Q4 2018 | $1,194,000 | -21.3% | 124,626 | -0.8% | 0.01% | 0.0% |
| Q3 2018 | $1,518,000 | -21.2% | 125,584 | +1.8% | 0.01% | -28.6% |
| Q2 2018 | $1,926,000 | +7.5% | 123,320 | +3.5% | 0.01% | +16.7% |
| Q1 2018 | $1,792,000 | +10.7% | 119,167 | +5.9% | 0.01% | +20.0% |
| Q4 2017 | $1,619,000 | -2.1% | 112,483 | +2.6% | 0.01% | -16.7% |
| Q3 2017 | $1,653,000 | +84.3% | 109,628 | +23.1% | 0.01% | +100.0% |
| Q2 2017 | $897,000 | +45.9% | 89,031 | +3.3% | 0.00% | +50.0% |
| Q1 2017 | $615,000 | +69.0% | 86,212 | +17.7% | 0.00% | +100.0% |
| Q4 2016 | $364,000 | -99.9% | 73,233 | -0.3% | 0.00% | -50.0% |
| Q3 2016 | $543,323,000 | +35.7% | 73,422 | +0.2% | 0.00% | 0.0% |
| Q2 2016 | $400,273,000 | -29.4% | 73,310 | +9.2% | 0.00% | 0.0% |
| Q1 2016 | $567,000,000 | +2.7% | 67,133 | +18.0% | 0.00% | 0.0% |
| Q4 2015 | $552,000,000 | +68813.9% | 56,873 | -0.7% | 0.00% | -33.3% |
| Q3 2015 | $801,000 | -99.9% | 57,271 | +1.4% | 0.00% | 0.0% |
| Q2 2015 | $799,532,000 | +7248.6% | 56,504 | +5550.4% | 0.00% | – |
| Q1 2015 | $10,880,000 | -74.6% | 1,000 | -95.2% | 0.00% | – |
| Q1 2014 | $42,791,000 | -9.8% | 20,672 | +2.5% | 0.00% | – |
| Q4 2013 | $47,414,000 | +0.3% | 20,176 | -1.0% | 0.00% | – |
| Q3 2013 | $47,277,000 | -2.3% | 20,378 | -1.8% | 0.00% | – |
| Q2 2013 | $48,375,000 | – | 20,762 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |